A recent therapeutic advance has been the approval of peptides targeting the glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) for obesity and weight loss. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.